Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	96267
Country	China

Received	2024-08-21 03:09
Peer-Review Started	2024-05-01 06:16
To Make the First Decision
Return for Revision	2024-09-16 16:50
Revised	2024-10-16 02:42
Second Decision	2024-11-05 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-05 07:42
Articles in Press	2024-11-05 07:42
Publication Fee Transferred	2024-11-08 08:08
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-11-21 03:40
Publish the Manuscript Online	2024-12-12 09:30

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Retrospective Cohort Study
Article Title	Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Fei-Da Wu, Hai-Feng Zhou, Wei Yang, Di Zhu, Bi-Fei Wu, Hai-Bin Shi, Sheng Liu and Wei-Zhong Zhou
Funding Agency and Grant Number
Corresponding Author	Wei-Zhong Zhou, MD, PhD, Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Gulou District, Nanjing 210029, Jiangsu Province, China. xmjbq007@163.com
Key Words	Hepatocellular carcinoma; Transarterial chemoembolization; Sintilimab; Lenvatinib; Immunotherapy; Programmed cell death 1; Prognosis
Core Tip	This study evaluates the efficacy and safety of combining transarterial chemoembolization (TACE) with lenvatinib and sintilimab compared to TACE with lenvatinib alone in patients with intermediate-advanced hepatocellular carcinoma. The results indicate that TACE with lenvatinib and sintilimab significantly improves overall survival (22.4 months vs 14.1 months) and progression-free survival (14.1 months vs 9.6 months), with a higher objective response rate (70% vs 55.6%). Notably, no severe adverse events were reported, suggesting that the combination therapy is effective and safe. These findings support the inclusion of sintilimab in hepatocellular carcinoma treatment regimens.
Publish Date	2024-12-12 09:30
Citation	<p>Wu FD, Zhou HF, Yang W, Zhu D, Wu BF, Shi HB, Liu S, Zhou WZ. Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma. <i>World J Gastrointest Oncol</i> 2025; 17(1): 96267</p>
URL	https://www.wjgnet.com/1948-5204/full/v17/i1/96267.htm
DOI	https://dx.doi.org/10.4251/wjgo.v17.i1.96267

Full Article (PDF)	WJGO-17-96267-with-cover.pdf
STROBE Statement	96267-STROBE-statement.pdf
Manuscript File	96267_Auto_Edited_005308.docx
Answering Reviewers	96267-answering-reviewers.pdf
Audio Core Tip	96267-audio.mp3
Biostatistics Review Certificate	96267-biostatistics-statement.pdf
Conflict-of-Interest Disclosure Form	96267-conflict-of-interest-statement.pdf
Copyright License Agreement	96267-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	96267-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	96267-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	96267-non-native-speakers.pdf
Supplementary Material	96267-supplementary-material.pdf
Peer-review Report	96267-peer-reviews.pdf
Scientific Misconduct Check	96267-scientific-misconduct-check.png
Scientific Editor Work List	96267-scientific-editor-work-list.pdf
CrossCheck Report	96267-crosscheck-report.pdf